Pluri Inc. PLUR
1.24 USD +0.05 (+3.82%)
At closeNov 6, 2026, 5:43 PM EST
1.07 -0.17 -13.38%
After hours · Nov 6, 5:43 PM ET
1.18 Day range 1.24
0.85 52-week range 4.45
- YTD
- -58.69%
- 1 year
- -61.99%
News
benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session Gainers Neumora Therapeutics (NASDAQ:NMRA) shares rose 11.9% to $0.41 during Tuesday's after-market session. The market value of their outstanding shares is at $73.8 million. Pulmonx (NASDAQ:LUNG)…
benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session Gainers Universe Pharmaceuticals (NASDAQ:UPC) stock moved upwards by 14.6% to $3.3 during Tuesday's pre-market session. The company's market cap stands at $14.4 million. Pomdoctor (NASDAQ:POM) stock…
benzinga.com Pluri And ZEO ScientifiX Announce Strategic Agreement To Expand Parties US Manufacturing And Commercialization Platform Serving Regenerative Medicine, Aesthetics, Wellness, And Longevity Markets Established U.S. commercial platform: ZEO contributes biologics manufacturing, scientific expertise, an existing product portfolio, physician relationships, and dedicated sales, marketing, and…
benzinga.com Pluri To Sell EIB Loan To Its Chairman And Largest Shareholder Alejandro Weinstein, Who Will Replace The EIB As Lender Upon completion of the transaction, Mr. Weinstein will replace the EIB as lender under the existing loan arrangements and will succeed to all of the lender’s rights and remedies thereunder, as in…
benzinga.com Pluri's Ever After Foods, Roslin Technologies Report Major Gains In Cultivated Meat Output Ever After Foods (EAF) and Roslin Technologies today announced results from their joint cultivated meat production program. Combining Roslin Technologies' advanced cell platform with Ever After Foods'
benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session Gainers IM Cannabis (NASDAQ:IMCC) stock rose 108.5% to $3.63 during Friday's pre-market session. The market value of their outstanding shares is at $1.0 million. Alaunos Therapeutics (NASDAQ:TCRT)…- benzinga.com Pluri Commences ~$3.3M Offering Of 2.229M Common Shares At $1.50 Per Share Pluri Inc. (NASDAQ:PLUR) (TASE: PLUR) ("Pluri"), a biotechnology company, leveraging its proprietary three-dimensional ("3D") cell expansion platform across two principal business verticals: (i) Human
benzinga.com Pluri Unit Cellav Health And Aesthetics Completes Cosmetic Regulatory Registration And Notification In The UK, Supporting Commercial Launch Of Regenativo+ The regulatory registration enables Cellav to commercially market its product in the UK and represents an important step in the Company's broader strategy to establish a global presence in the…- benzinga.com Pluri Announces Chairman Alejandro Weinstein Has Invested $17M+In PLUR, Including A $1.25M Advance Investment Made In June 2026 His growing commitment comes as Pluri advances its transition from platform development toward commercial execution, with an increasing focus on longevity and planned commercial activity in the…
- benzinga.com Pluri Announces Completion Of Development And U.S. Cosmetic Product Listings For Two Flagship Regenerative Aesthetic Products, Regenativo+ And Placento+, Clearing Way For U.S. Commercial Launch Pluri Inc. (NASDAQ:PLUR) (TASE: PLUR), a biotechnology company pioneering 3D cell-expansion technology to power scalable cell-based products across therapeutics, regenerative aesthetics, longevity…
- benzinga.com Pluri Signs Agreement With Beneficiary Owned By Chairman Alejandro Weinstein For Additional $2.5M Investment In Co. Pluri Inc. ("Pluri" or the "Company") (Nasdaq, TASE: PLUR), a biotechnology company leveraging a proprietary cell-based platform across multiple commercial verticals, today announced that an entity…
- benzinga.com Pluri Subsidiary Puri Biotech Secures Patent Covering 3D Immune Cell Expansion Tech The China National Intellectual Property Administration (CNIPA) has granted Pluri Biotech Ltd., a wholly owned subsidiary of Pluri, a patent covering its proprietary 3D immune cell expansion and…
- benzinga.com Pluri Q2 EPS $(0.71) Misses $(0.65) Estimate, Sales $198.000K Miss $638.000K Estimate Pluri (NASDAQ:PLUR) reported quarterly losses of $(0.71) per share which missed the analyst consensus estimate of $(0.65) by 9.23 percent. This is a 33.96 percent decrease over losses of $(0.53) per…
- benzinga.com Pluri Completes First Phase Of Its Program With Resbiomed Technologies OOD Over Placenta-Derived Processing, Bioprocessing Capabilities Pluri, Inc.
benzinga.com Pluri Expands Manufacturing Agreement With Remedy Cell, Advances Clinical-Grade Production Pluri, Inc. ("Pluri", the "Company", "we" or "us") (Nasdaq, TASE: PLUR), a leading biotechnology company leveraging its proprietary platform for cell-based solutions through a collaborative network…- benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session
- benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session
- benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session
benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session - benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session
- benzinga.com Stocks That Hit 52-Week Lows On Friday During Friday, 125 stocks hit new 52-week lows.
benzinga.com Stocks That Hit 52-Week Lows On Tuesday On Tuesday, 456 stocks hit new 52-week lows.- benzinga.com Stocks That Hit 52-Week Lows On Monday On Monday, 429 stocks made new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Friday During Friday's session, 574 stocks hit new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Friday On Friday, 122 stocks hit new 52-week lows.
benzinga.com Stocks That Hit 52-Week Lows On Thursday On Thursday, 529 companies set new 52-week lows.